This website is intended for US healthcare professionals only.

For severe DEB,

Patients need sustained wound healing1,2

Rowan, a real patient with severe DEB

Rowan, a real patient with severe DEB

For this ultra-rare disease, sustained wound healing must become more common2

Severe dystrophic epidermolysis bullosa (DEB) is characterized by large, chronically open wounds that are associated with increased pruritus, pain, and complications including increased incidence of infection, and a high risk of aggressive squamous cell carcinoma.3,4

Advancement in clinical research is helping us see the possibilities.1

Sign up to stay informed on advances in severe DEB

*Required fields.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

References:  1. Keith AR, Twaroski K, Ebens CL, Tolar J. Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa. Expert Opin Biol Ther. 2020;20(8):911-923. doi:10.1080/14712598.2020.1740678.  2. Feinstein JA, Bruckner AL, Chastek B, Anderson A, Roman J. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367. doi:10.1186/s13023-022-02509-0.  3. Huitema L, Phillips T, Alexeev V, Igoucheva O. Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2021;30(12):1724-1733. doi:10.1111/exd.14411.  4. Mellerio JE, Kiritsi D, Marinkovich MP, et al. Mapping the burden of severe forms of epidermolysis bullosa: implications for patient management. JAAD Int. 2023;11:224-232. doi:10.1016/j.jdin.2023.02.016.